Isomorphic Labs, the AI drug design company founded by Sir Demis Hassabis, has entered a strategic research collaboration with MSD — the brand under which Merck & Co. operates outside the United States and Canada. The partnership was announced on Isomorphic Labs' own website on November 19, 2026, just two days after the company closed a record $5 billion Series C funding round, and it pairs Isomorphic's AI-first drug discovery engine with one of the world's largest pharmaceutical data troves.

The deal is the latest sign that big pharma is moving from experimenting with AI drug design to embedding it in core discovery pipelines, and it marks a significant piece of AI business news in the fast-consolidating intersection of frontier AI and biotechnology. For Isomorphic, it is also the first major validation of its platform since its landmark fundraise — and an early test of whether AI-designed molecules can move toward patients at a pace traditional discovery cannot match.

What the Collaboration Covers

In its announcement, Isomorphic Labs described the collaboration as bringing together "Isomorphic Labs' AI approach to drug discovery with MSD's rich proprietary data resources and deep discovery experience." Financial terms were not disclosed in the announcement, and neither party has published the number or type of drug targets covered.

The technological centerpiece is IsoDDE, the Isomorphic Labs Drug Design Engine — which the company calls a "world-leading, modality-agnostic drug design engine comprised of foundational AI models," providing "the predictive fidelity required to navigate novel biological systems with unprecedented accuracy." In plain terms: rather than specializing in one drug modality, Isomorphic's models are designed to work across many classes of therapeutic molecules, predicting how candidates behave in biological systems before anything is synthesized.

Trade press coverage has framed the deal specifically around cancer. Fierce Biotech reported that Isomorphic "adds Merck to AI drug discovery roster days after $5B raise," while Drug Discovery & Development described Merck as joining as an oncology partner, and Contract Pharma summarized the collaboration as AI-driven cancer drug discovery. That positioning matters: oncology is both one of pharma's largest research budgets and one of its most scientifically punishing categories, where the vast majority of clinical candidates fail.

Expectation management, however, remains essential. As Medical Daily noted in its coverage, no candidate designed with Isomorphic's AI has yet been tested in animals or humans. The company's own materials emphasize design and discovery — the earliest, preclinical end of the pipeline — rather than approved medicines.

A Fast Follow to a Record Raise

The timing is no accident. On November 17, Isomorphic Labs announced a $5 billion Series C that industry outlet BioSpace reported as the largest venture fundraising round in biotech history, co-led by Greenoaks and Sequoia Capital according to Bloomberg, with Andreessen Horowitz and continued significant investment from Alphabet joining existing backers including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The round came only months after the company's $2.1 billion Series B in May 2026.

The MSD deal arrived 48 hours later, transforming the raise's promise into a concrete commercial partnership with a top-five global pharmaceutical company. Fierce Biotech's framing — Merck joining Isomorphic's pharma collaboration "roster" — underscores that this is now a portfolio of big-pharma relationships rather than a one-off experiment.

The company's leadership context amplifies the stakes. Hassabis, who won the 2024 Nobel Prize in Chemistry for protein structure prediction, stepped back from his role as Google DeepMind's CEO earlier this year to devote himself fully to Isomorphic. The company's president, Max Jaderberg, has framed the ambition in sweeping terms: "Even if we could accurately predict the properties of a billion molecules, we would still have explored only a tiny fraction of the possible design space. We're going further than prediction, with models that can learn how to navigate that space to find a universe of possibilities beyond human intuition."

Why Pharma Keeps Signing AI Deals

The structure of the announcement — Isomorphic's models plus MSD's proprietary data — reflects the current logic of AI-pharma deals. Foundation models for biology are only as good as the experimental data used to train and validate them, and pharmaceutical companies hold decades of high-quality, proprietary assay and discovery data that AI-native startups cannot replicate. Deals like this one effectively trade the pharma company's data and disease expertise for access to a design engine that can search chemical space orders of magnitude faster than traditional medicinal chemistry.

What neither party has shown yet is clinical proof. That is the industry's open question, and it is why Isomorphic's stated goal for its $5 billion raise — advancing its lead internal programs toward the clinic, as TechCrunch reported — will be watched as closely as any partnership. Investors and partners are, in effect, placing parallel bets: that AI-designed candidates will reach human trials faster, fail cheaper, and hit better biology than conventionally discovered ones.

For MSD, the collaboration adds an AI-first discovery capability to its oncology arsenal without the multi-year cost of building one from scratch. For Isomorphic, it provides revenue, data, and a demanding industrial partner at precisely the moment its funding has peaked. The next milestone that matters is not another deal — it is the first AI-designed candidate from these pipelines entering the clinic.

---

Stay Ahead of AI

Get the latest AI news, analysis, and breakthroughs — all in one place.

Read more AI news →